Highly recurrent TERT promoter mutations in human melanoma
- PMID: 23348506
- PMCID: PMC4423787
- DOI: 10.1126/science.1229259
Highly recurrent TERT promoter mutations in human melanoma
Abstract
Systematic sequencing of human cancer genomes has identified many recurrent mutations in the protein-coding regions of genes but rarely in gene regulatory regions. Here, we describe two independent mutations within the core promoter of telomerase reverse transcriptase (TERT), the gene coding for the catalytic subunit of telomerase, which collectively occur in 50 of 70 (71%) melanomas examined. These mutations generate de novo consensus binding motifs for E-twenty-six (ETS) transcription factors, and in reporter assays, the mutations increased transcriptional activity from the TERT promoter by two- to fourfold. Examination of 150 cancer cell lines derived from diverse tumor types revealed the same mutations in 24 cases (16%), with preliminary evidence of elevated frequency in bladder and hepatocellular cancer cells. Thus, somatic mutations in regulatory regions of the genome may represent an important tumorigenic mechanism.
Figures
Similar articles
-
TERT promoter mutations in familial and sporadic melanoma.Science. 2013 Feb 22;339(6122):959-61. doi: 10.1126/science.1230062. Epub 2013 Jan 24. Science. 2013. PMID: 23348503
-
An interaction proteomics survey of transcription factor binding at recurrent TERT promoter mutations.Proteomics. 2016 Feb;16(3):417-26. doi: 10.1002/pmic.201500327. Epub 2016 Jan 8. Proteomics. 2016. PMID: 26553150
-
TERT promoter mutations in melanoma render TERT expression dependent on MAPK pathway activation.Oncotarget. 2016 Aug 16;7(33):53127-53136. doi: 10.18632/oncotarget.10634. Oncotarget. 2016. PMID: 27449293 Free PMC article.
-
TERT promoter mutations in cancer development.Curr Opin Genet Dev. 2014 Feb;24:30-7. doi: 10.1016/j.gde.2013.11.005. Epub 2013 Dec 20. Curr Opin Genet Dev. 2014. PMID: 24657534 Review.
-
TERT promoter mutations and GABP transcription factors in carcinogenesis: More foes than friends.Cancer Lett. 2020 Nov 28;493:1-9. doi: 10.1016/j.canlet.2020.07.003. Epub 2020 Aug 6. Cancer Lett. 2020. PMID: 32768523 Review.
Cited by
-
Exploring hTERT promoter methylation in cutaneous T-cell lymphomas.Mol Oncol. 2022 May;16(9):1931-1946. doi: 10.1002/1878-0261.12946. Epub 2021 Oct 12. Mol Oncol. 2022. PMID: 33715271 Free PMC article.
-
Therapeutic targeting of FOS in mutant TERT cancers through removing TERT suppression of apoptosis via regulating survivin and TRAIL-R2.Proc Natl Acad Sci U S A. 2021 Mar 16;118(11):e2022779118. doi: 10.1073/pnas.2022779118. Proc Natl Acad Sci U S A. 2021. PMID: 33836600 Free PMC article.
-
Cancer-associated TERT promoter mutations abrogate telomerase silencing.Elife. 2015 Jul 21;4:e07918. doi: 10.7554/eLife.07918. Elife. 2015. PMID: 26194807 Free PMC article.
-
Genotyping of cutaneous melanoma.Chin Clin Oncol. 2014 Sep;3(3):27. doi: 10.3978/j.issn.2304-3865.2014.03.01. Chin Clin Oncol. 2014. PMID: 25632386 Free PMC article.
-
Telomere maintenance and the etiology of adult glioma.Neuro Oncol. 2015 Nov;17(11):1445-52. doi: 10.1093/neuonc/nov082. Epub 2015 May 25. Neuro Oncol. 2015. PMID: 26014050 Free PMC article. Review.
References
-
-
Materials and methods are available as supplementary materials on
Science Online.
-
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases